SARS-CoV-2 Seroprevalence and Symptom Onset in Culturally Linked Orthodox Jewish Communities Across Multiple Regions in the United States.
Adolescent
Adult
Aged
Aged, 80 and over
COVID-19
/ epidemiology
COVID-19 Serological Testing
California
/ epidemiology
Connecticut
/ epidemiology
Cross-Sectional Studies
Culturally Competent Care
Disease Outbreaks
Disease Transmission, Infectious
Female
Holidays
Humans
Jews
/ statistics & numerical data
Judaism
Male
Michigan
/ epidemiology
Middle Aged
Minority Groups
New Jersey
/ epidemiology
New York
/ epidemiology
Public Health
Residence Characteristics
SARS-CoV-2
Seroepidemiologic Studies
United States
/ epidemiology
Young Adult
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
entrez:
10
3
2021
pubmed:
11
3
2021
medline:
19
3
2021
Statut:
epublish
Résumé
Data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in the United States are still emerging. To elucidate SARS-CoV-2 seroprevalence and symptom onset in a culturally linked community across 5 states in the United States. This cross-sectional study included adults (aged ≥18 years) recruited from the orthodox Jewish community across 5 states (California, Connecticut, Michigan, New Jersey, and New York) in 3 geographically distinct areas of the United States between May 13 and July 6, 2020. Participants completed an online survey and underwent SARS-CoV-2 antibody testing. Seroprevalence and date of symptom onset of SARS-CoV-2. Overall, 9507 adults (mean [SD] age, 39.6 [15.0] years; 3777 [39.7%] women) completed the SARS-CoV-2 survey, of whom 6665 (70.1%) had immunoglobin G anti-SARS-CoV-2 antibody levels assessed. A high seroprevalence of SARS-CoV-2 antibodies was observed across all communities, with the highest proportion of positive testing observed in New Jersey (1080 of 3323 [32.5%]) and New York (671 of 2196 [30.6%]). Most individuals with a positive SARS-CoV-2 immunoglobin G antibody test reported a date of symptom-onset between March 9 and March 31, 2020 (California: 135 of 154 [87.7%]; Connecticut: 32 of 34 [94.1%]; Michigan: 44 of 50 [88.0%]; New Jersey: 964 of 1168 [82.5%]; New York: 571 of 677 [84.3%]). This start date was coincident with the Jewish festival of Purim, celebrated March 9 to 10, 2020, with extensive intracommunity spread in the weeks following (mean and mode of peak symptom onset, March 20, 2020), occurring in the absence of strong general and culture-specific public health directives. This cross-sectional study of orthodox Jewish adults across the US found that socioculturally bound communities experienced early parallel outbreaks in discrete locations, notably prior to substantive medical and governmental directives. Further research should clarify optimal national, local, community-based, and government policies to prevent outbreaks in social and cultural communities that traditionally gather for holidays, assemblies, and festivals.
Identifiants
pubmed: 33688968
pii: 2777318
doi: 10.1001/jamanetworkopen.2021.2816
pmc: PMC7948060
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e212816Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL139854
Pays : United States
Références
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32513859
Int J Crit Illn Inj Sci. 2020 Apr-Jun;10(2):49-52
pubmed: 32904563
J Travel Med. 2020 May 18;27(3):
pubmed: 32109274
Infect Dis Health. 2020 Aug;25(3):219-221
pubmed: 32305323
MMWR Morb Mortal Wkly Rep. 2020 May 08;69(18):551-556
pubmed: 32379733
Science. 2020 Jun 26;368(6498):1481-1486
pubmed: 32350060
Health Soc Care Community. 2011 May;19(3):225-49
pubmed: 21208326
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
J Med Internet Res. 2020 Sep 10;22(9):e21562
pubmed: 32791492
Int J Infect Dis. 2020 Jul;96:219-221
pubmed: 32389851
JAMA Intern Med. 2020 Sep 1;180(9):1156-1163
pubmed: 32356867
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):606-610
pubmed: 32407303
Pers Soc Psychol Rev. 2016 Feb;20(1):27-48
pubmed: 25673322
JAMA Intern Med. 2020 Nov 24;:
pubmed: 33231628
JAMA Intern Med. 2020 Jul 21;:
pubmed: 32692365
Nature. 2021 Feb;590(7844):146-150
pubmed: 33142304
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675